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A B S T R A C T
Reactive oxygen species (ROS) have been implicated in tumorigenesis (tumor initiation, tumor progression, and
metastasis). Of the many cellular sources of ROS generation, the mitochondria and the NADPH oxidase family of
enzymes are possibly the most prevalent intracellular sources. In this article, we discuss the methodologies to
detect mitochondria-derived superoxide and hydrogen peroxide using conventional probes as well as newly de-
veloped assays and probes, and the necessity of characterizing the diagnostic marker products with HPLC and
LC-MS in order to rigorously identify the oxidizing species. The redox signaling roles of mitochondrial ROS, mi-
tochondrial thiol peroxidases, and transcription factors in response to mitochondria-targeted drugs are highlighted.
ROS generation and ROS detoxiﬁcation in drug-resistant cancer cells and the relationship to metabolic repro-
gramming are discussed. Understanding the subtle role of ROS in redox signaling and in tumor proliferation,
progression, and metastasis as well as the molecular and cellular mechanisms (e.g., autophagy) could help in the
development of combination therapies. The paradoxical aspects of antioxidants in cancer treatment are highlighted
in relation to the ROS mechanisms in normal and cancer cells. Finally, the potential uses of newly synthesized
exomarker probes for in vivo superoxide and hydrogen peroxide detection and the low-temperature electron
paramagnetic resonance technique for monitoring oxidant production in tumor tissues are discussed.
1. Introduction
“Nonetheless, from a biological point of view, it is beginning to look as if
ROS are neither cellular heroes nor villains—but instead something that
occupies that always entertaining, captivating and fertile middle ground.”
Holmstrom and Finkel (Nature Reviews) [1]
Holmstrom and Finkel elucidated the dual nature of reactive oxygen
species (ROS) that elicits both harmful and beneﬁcial eﬀects in cells and
the state of the ROS in diseases including cancer [1]. Also, the authors
emphasized the need to appreciate the diﬀering chemistry of various
ROS (e.g., superoxide radical anion [O2•–] and hydrogen peroxide
[H2O2]) in redox-dependent pathways, highlighting the importance of
developing methods to detect oxidants in vivo. In the present article, we
address some of the gaps in our knowledge concerning ROS and redox
signaling in cancer biology. Further, we discuss state-of-the-art assays
and probes for detecting O2•–, H2O2, and other oxidants in tumor cells in
response to treatment with OXPHOS-targeting drugs, and their poten-
tial applications for the detection of mitochondria-derived ROS during
tumorigenesis and metabolic reprogramming. The paradoxical role of
ROS in tumor proliferation and tumor suppression [2] is discussed in
the context of redox signaling mechanisms. Similarly, the paradoxical
eﬀects of antioxidants in tumorigenesis and tumor progression are
discussed. Understanding the roles of mitochondrial ROS and redox
signaling pathways in cancer biology may help in the discovery of re-
latively nontoxic and targeted therapies.
2. ROS: The most cited, most popular, yet most ambiguous term
The term “ROS” does not relate to a single species; rather, it covers a
range of small molecule oxidizing, nitrosating, nitrating, halogenating,
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and thiol-reactive species, produced in biological systems. The use of
ROS as an umbrella term for oxidants has been previously criticized
because of its nonspeciﬁcity and ambiguity [3,4]. One of the authors of
this article (BK) was also critical of using ROS as an umbrella term for
all oxidants [3]. However, ROS as a term for small-molecule oxidants is
now universally embraced and frequently used in novel biological set-
tings by investigators in many areas of research, including cancer
biology. Thus, it was decided that the same umbrella term, ROS, would
be adapted for oxidants. That said, the lack of proper characterization
of the structure of oxidants could seriously hamper our eﬀorts to un-
cover new and novel oncogenic signaling pathways involved. In order
to fully understand the signaling roles of ROS, it is essential to under-
stand more about the nature and identity of the species, whether it is
O2•–, H2O2, lipid hydroperoxide, or an electrophile such as 4-hydro-
xynonenal derived from lipid oxidation. Proper identiﬁcation of the
structure of the ROS will also help us understand the mechanisms of
action of drugs and drug resistance in cancer. In some ways, ROS levels
and signaling are also modulated by other signaling molecules like ni-
tric oxide (•NO) via a nearly diﬀusion-controlled reaction between •NO
and O2•– [5], generating a potent oxidizing and nitrating molecule,
peroxynitrite (ONOO–), also referred to as reactive nitrogen species
(RNS). Although there is ample evidence for the occurrence of this type
of mechanism and its biological relevance in cardiovascular and neu-
robiological systems [6,7], there is very little published data on the •NO
and O2•– interaction and its signaling ramiﬁcations in cancer biology.
Many probes (ﬂuorescent and chemiluminescent) have been previously
employed to identify ROS, but there is still a lot of confusion in this ﬁeld
due to a lack of mechanistic rigor and the artifacts generated from re-
ductive/oxidative activation of the probes themselves [8,9]. Most of
these limitations have, however, been previously addressed [10,11].
Irrespective of the methodology used to detect ROS, it is clear that
oxidants are involved, either as a major player or as a bystander, in the
underlying biology. On the positive side, there now exist more speciﬁc
probes and assays for selective identiﬁcation of various ROS. Published
data from independent laboratories are in agreement that identiﬁcation
of speciﬁc products formed from ROS interaction with ﬂuorescent
probes is crucial for determining the identity of ROS [12,13]. A reaction
between O2•– and hydroethidine (HE) results in the formation of a very
speciﬁc product, 2-hydroxyethidium (2-OH-E+); this product is not
formed from the reaction between HE and other biologically relevant
oxidants such as H2O2, singlet oxygen, lipid hydroperoxides, perox-
ynitrite, HOCl, and •NO2 [14,15]. This marker product derived from the
O2•– and HE reaction (2-OH-E+) can be unambiguously detected by
rapid high-performance liquid chromatography (HPLC) and liquid
chromatography–mass spectrometry (LC-MS) methods [16]. However,
numerous publications using HE-derived ﬂuorescence still posit that
ethidium (E+) is the product of the O2•– reaction with HE, whereas it
has been clearly established by us and others that E+ is not the product
of the reaction between O2•– and HE (Fig. 1) [17,18]. Evidence also
exists that the reaction chemistry between O2•– and other analogs of HE
including Mito-SOX is similar to that of HE [19,20]. The lack of ap-
preciation and the misconception of the chemistry and the mechanism
of action of O2•– with HE, Mito-SOX (a mitochondria-targeted HE), and
other HE analogs are responsible for the multitude of publications in
biomedical research, including cancer, that suggest or conclude the
intermediacy of O2•– formation [21,22].
Most assays to detect H2O2 are based on peroxidatic oxidation of
probes such as Amplex Red in an extracellular milieu [23]. So far, very
little information is available on chemical probes that react directly
with H2O2 to form a diagnostic product. However, recently activity in
this area has increased [24–26]. Boronate-based ﬂuorescence probes
react with H2O2 stoichiometrically (albeit very slowly, with the rate
constant of 1–2 M−1 s−1) to form ﬂuorescent products [27,28]. Bor-
onates also react with peroxynitrite nearly a million times faster than
with H2O2, forming a major product (90%) that is the same as the
product derived from the boronate/H2O2 reaction and a very
characteristic and diagnostic minor product (5–10%) [27,29]. If the
product that is highly diagnostic for peroxynitrite is not detected, it is
likely that the major product is not formed from peroxynitrite (Fig. 2).
Mitochondria-targeted boronates (meta-MitoB) were used to detect
H2O2 in vivo [30,31]. We used an isomer, ortho-MitoB, to detect H2O2
because of its ability to distinguish between peroxynitrite and H2O2
[28,32,33]. Predicting the cellular response (activation of signaling
pathways) to speciﬁc ROS requires a thorough understanding of its
chemical properties in a biological setting.
3. Mitochondria, Nox, and ROS
Two major sources of ROS in cancer are mitochondria and nicoti-
namide adenine dinucleotide phosphate (NADPH) oxidases [34,35].
Mitochondrial respiratory chain complexes are generally thought to be
responsible for generating ROS, O2•–, and H2O2, in particular. Research
in the early 1970s by Chance and collaborators provided the ﬁrst evi-
dence for mitochondrial generation of ROS [36]. Although O2•– for-
mation in mitochondria was not convincingly demonstrated, Chance
and coworkers demonstrated mitochondrial generation of H2O2 using a
sensitive spectrophotometric method [36]. H2O2 was measured in the
cytosolic extracts derived from mitochondria using the absorption
changes that occur during the catalytic cycle of cytochrome c perox-
idase and H2O2. This is a fundamentally signiﬁcant discovery revealing
an aberrant oxygen metabolism (albeit less than 1%) during mi-
tochondrial respiration [37].
Complex III in the mitochondrial respiratory chain could form O2•–
when mitochondria were treated with the inhibitor, antimycin.
Mitochondrial complex I is another source of O2•– generation in the
presence of rotenone that inhibits complex I [38]. Superoxide from
complex I is also formed under conditions of a high proton motive force
and reduced coenzyme Q pool (i.e., a situation known as the reverse
electron transport mechanism wherein electrons are driven back
through complex I) [39].
That mitochondria also generate O2•– and H2O2 under in vivo con-
ditions is supported by the existence of manganese superoxide dis-
mutase (MnSOD) and other antioxidant enzymes (peroxidases and
peroxiredoxins) in the mitochondrial matrix, and by the pathological
consequences (e.g., mitochondrial oxidative stress including DNA da-
mage) resulting from their deﬁciency.
Nox enzymes are emerging as a promising target for anticancer drug
development due to mounting evidence that suggests that NADPH/Nox-
derived ROS inhibit tumor apoptosis and stimulate tumor proliferation
[40,41]. Several Nox isoforms (e.g., Nox2 and Nox4) have been pro-
posed as potential therapeutic targets in the treatment of cancer and
other diseases [42]. Unlike other redox enzymes for which ROS gen-
eration is an “accidental” byproduct of their primary catalytic function,
the only known function of Nox enzymes (Nox1-5, Duox1-2) is gen-
eration of ROS (e.g., O2•– and H2O2) [43]. Nox2 forms both O2•– and
H2O2 (via dismutation of O2•–); however, published reports suggest that
Nox4 primarily generates H2O2 (90%) [44,45]. A major impediment to
advancing Nox research in cancer biology is the lack of availability of
selective inhibitors of Nox isoforms [46]. This, in turn, had been due to
the lack of assays selective for O2•– and H2O2 using speciﬁc probes, but
this hurdle has been largely overcome with recent discoveries of new
probes and sensitive assays for detection of ROS and RNS [47].
Oncogenic KRAS was reported to promote ROS/RNS generation by
increasing the expression and activity of Nox enzymes at the tumor cell
membrane [48]. However, it is likely that Nox activity is modulated by
changes in mitochondrial bioenergetics. Although there are reports in
the vascular biology literature of potential “cross-talk” between mi-
tochondrial ROS and Nox activation [49], there is no information, to
our knowledge, on the modulatory role of mitochondrial metabolism on
Nox/ROS metabolism and oxidative signaling in cancer biology. Al-
though, this particular aspect is outside the scope of the present review,
understanding how modiﬁcations of cancer cell bioenergetics and
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metabolism aﬀect the NADPH/Nox/ROS pathway or phosphorylation
of the upstream target in Nox activation could be highly signiﬁcant in
metabolism-based drug therapeutics.
4. Assays and probes for intracellular detection of ROS (O2•– and
H2O2)
Most publications concerning ROS production in biology, including
cancer biology, involve the use of redox dyes—dichlorodihydro-
ﬂuorescein (DCFH), HE, and Mito-SOX (Fig. 3)—and their oxidation
products were detected by ﬂuorescence. Neither O2•– nor H2O2 was
reported to react at any appreciable rate with DCFH [50]. Measuring the
oxidation of redox dyes by ﬂuorescence is deﬁnitely not the same as mea-
suring cellular ROS. This is an important and signiﬁcant distinction that
is validated by a thorough understanding of the chemistry (kinetics,
stoichiometry, and analyses of intermediates and products) established
for these dyes in the presence of various biologically relevant reactive
oxygen and nitrogen species. Investigators have used DCFH-derived
green ﬂuorescence for detecting intracellular H2O2 and HE-, and Mito-
SOX-derived red ﬂuorescence for detecting intracellular and mi-
tochondrial generation of O2•– [51,52]. However, most likely the in-
vestigators were monitoring the oxidation of the redox dyes (DCFH, HE,
and Mito-SOX) through a similar peroxidatic mechanism (iron, heme
iron, or cytochrome c-catalyzed) in the presence of O2•– and H2O2
(Fig. 3) [20]. Enhanced ﬂuorescence was related to tumorigenesis and
metabolic reprogramming in tumor cells [53,54]. However, enhanced
ﬂuorescence from oxidation of redox dyes cannot be equated to en-
hanced O2•– formation. As reiterated earlier, it is essential to separate
and identify the speciﬁc products derived from the O2•– reaction with
HE and Mito-SOX under these conditions before implicating the inter-
mediacy of O2•– and/or H2O2 in redox-dependent processes (Fig. 4).
We and others have shown that inhibition of complex I in mi-
tochondria results in increased production of O2•– and other one-elec-
tron oxidants [55]. We used HPLC-based analyses to determine
Fig. 1. HE-derived nonspeciﬁc oxidation and
O2•–-speciﬁc hydroxylation products. The ﬂuores-
cence spectra of the nonspeciﬁc oxidation product
E+ (10 µM, right axis) and O2•–-dependent hydro-
xylation product 2-OH-E+ (10 µM, left axis) in the
presence of DNA show a signiﬁcant overlap.
(Obtained from Ref. [15]. Reprinted from H. Zhao, J.
Joseph, H.M. Fales, E.A. Sokoloski, R.L. Levine, J.
Vasquez-Vivar, B. Kalyanaraman, Detection and
characterization of the product of hydroethidine and
intracellular superoxide by HPLC and limitations of
ﬂuorescence, Proceedings of the National Academy
of Sciences of the United States of America 102(16)
(2005) 5727–5732, Copyright 2005 National
Academy of Sciences.).
Fig. 2. H2O2 and peroxynitrite-induced formation of major and minor products
derived from o-MitoPhB(OH)2. Reaction between H2O2 and o-MitoB stoichiometrically
generates the only product, o-Mito-PhOH, whereas the reaction between ONOO– and o-
MitoB(OH)2 produces a major product, o-Mito-PhOH, and a minor cyclized product that is
highly characteristic for reaction with ONOO–. (Obtained from Ref. [55]. Reprinted from
Interface Focus, 7, B. Kalyanaraman, G. Cheng, M. Hardy, O. Ouari, A. Sikora, J. Zielonka,
M. Dwinell, Mitochondria-targeted metformins: anti-tumor and redox signaling me-
chanisms, 20160109, Copyright 2017.).
Fig. 3. Relationship between enhanced oxidation of redox dyes and redox-depen-
dent processes. Enhanced oxidation of redox dyes leading to enhanced ﬂuorescence
intensity during tumorigenesis, metabolic reprogramming, and drug resistance.
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products formed from redox dyes [56–58]. HE is cell-permeable and
can be used to detect intracellular O2•–, both cytosolic and mitochon-
dria-derived. Several mitochondria-targeted agents inhibit complex I
activity in multiple cancer cell lines (e.g., lung cancer, pancreatic
cancer) [59,60]. Incubation with HE under conditions inhibiting mi-
tochondrial complex I in cancer cells induces formation of O2•– and
other oxidants. Fig. 5A shows that Mito-metformin (a mitochondria-
targeted derivative of metformin) enhanced the formation of 2-OH-E+,
a superoxide-speciﬁc product; E+; and diethidium (E+-E+). Because of
the interference (spectral overlap) between 2-OH-E+ and E+, it is im-
possible to use the ﬂuorescence results to make a deﬁnite conclusion on
the changes in O2•– production. E+ is typically detected at levels at least
10-fold higher than 2-OH-E+ (Fig. 5A).
To detect H2O2 generated in cells, the probe o-MitoPhB(OH)2 is used
(Fig. 2). The meta analog, m-MitoPhB(OH)2 (known as the MitoB
probe), can also be used [55]. Although both probes react stoichio-
metrically with H2O2 to form the respective phenolic product, Mito-
PhOH (also called MitoP), only the ortho-substituted probe forms
characteristic cyclized and nitrated minor products upon reaction with
peroxynitrite (ONOO–) [28,32]. Failure to detect the cyclic and nitrated
products would deﬁnitively indicate that ONOO– is not the oxidant
responsible for oxidizing o-MitoPhB(OH)2 to o-MitoPhOH. The meta
analog will not form the cyclic minor product upon reaction with
ONOO–.
Intracellular H2O2 formation induced by Mito-metformin10 (Mito-
Met10) in PDACs was measured using the probe, o-MitoPhB(OH)2.
MiaPaCa-2 pancreatic cancer cells were treated for 24 h with Mito-
Met10 followed by monitoring of cellular oxidant using o-MitoPhB
(OH)2. As shown in Fig. 5B, the intracellular levels of both the probe
and the product were quantitated. Mito-Met10 induced an increase in
the H2O2-derived product from o-MitoPhB(OH)2. It has been mentioned
that H2O2 does not react rapidly with boronates. Peroxiredoxin en-
zymes react with H2O2 a million times faster than do boronates, and so
the extent of the H2O2 reaction with boronate probes is likely to be very
small. Protein hydroperoxides react with boronate probes ca. 10 times
faster than H2O2, and thus can also be responsible for the oxidation of
the probe during increased production of O2•– and H2O2 [61]. As
mentioned above, in addition to boronate probes, Amplex Red/horse-
radish peroxidase may be used to measure extracellularly released
H2O2.
In contrast to the frequently used artifact-prone DCFH probe (that
self-stimulates H2O2 formation via intermediate radical formation), the
MitoB probes do not self-promote H2O2 and, as a result, measurement
of the product truly reﬂects the H2O2 (or other hydroperoxide) induced
in cells and not artifactually formed from probe oxidation/reduction.
5. Monitoring intracellular ﬂuorescence derived from redox
probes such as HE and Mito-SOX does not measure intracellular or
mitochondrial superoxide
HE is a redox active probe that is synthesized from a two-electron
reduction of E+ [14,15]. HE can also be oxidized to E+ through non-
speciﬁc mechanisms in cells. In addition, dimeric products (non-
ﬂuorescent, e.g. E+-E+) are also formed from HE (Fig. 6) [20]. In cells,
E+ is typically present at a much higher concentration than 2-OH-E+
(see for example Fig. 5A). Fig. 1 shows a signiﬁcant overlap in the
ﬂuorescence spectra of E+ and 2-hydroxyethidium. Thus, in an in-
tracellular milieu, where the nonspeciﬁc oxidation of HE to E+ is
usually much higher, the observed ﬂuorescence intensity is mostly de-
rived from E+ and, therefore, cannot be attributed to the O2•–/HE re-
action-derived product, 2-OH-E+. Because the chemistry between O2•–
and HE analogs is the same, irrespective of the detection modalities,
whether confocal microscopy or ﬂow cytometry, ﬂuorescence-based
approaches using the currently available probes are not suitable for
selective detection of O2•–. Only the HPLC or LC-MS approach, utilizing
authentic standards of the oxidation products, can be used to measure
2-OH-E+ or its analogs. Under the same conditions, the level of the
probe and nonspeciﬁc E+ and the dimeric products of HE oxidation
should also be measured.
Mito-SOX is a mitochondria-targeted analog of HE that has a six-
carbon aliphatic chain containing a triphenylphosphonium group. Mito-
SOX reacts with superoxide, hemes, and one-electron oxidizing agents
in exactly the same manner as does HE [20,62]. Superoxide reacts with
Mito-SOX and its radical, forming 2-hydroxylated Mito-SOX (2-OH-
Mito-E+). Nonspeciﬁc reaction products of Mito-SOX are Mito-E+ and
the dimeric products including Mito-E+-Mito-E+. Very similar to 2-OH-
E+ and E+ (Fig. 1), both 2-OH-Mito-E+ and Mito-E+ share overlapping
ﬂuorescence spectra [63]. Mito-E+ is typically formed in a much higher
concentration than 2-OH-Mito-E+. Thus, the ﬂuorescence obtained
using Mito-SOX does not measure mitochondrial O2•– but simply in-
dicates the oxidation of Mito-SOX. Unfortunately, a multitude of pub-
lications claim to have detected mitochondrial O2•– on the basis of in-
creased ﬂuorescence intensity from cancer cells using Mito-SOX as the
ROS detection probe [64,65]. As with HE, the only way to detect mi-
tochondrial O2•– using Mito-SOX is to measure the marker product, 2-
OH-Mito-E+, using HPLC-based techniques. The standard for this pro-
duct can be synthesized using Mito-SOX and Fremy's salt [17,66]. Be-
cause mitochondria-targeted probes containing the triphenylpho-
sphonium cationic moiety (TPP+) accumulate in tumor cell
mitochondria more than in normal cells, it is important to perform a
dose-response measurement investigating the eﬀect of probes such as
Mito-SOX on mitochondrial function in diﬀerent cancer cell phenotypes
[67].
Mitochondria-derived ROS are often indicated as MROS or mtROS.
Mito-SOX is typically used in these studies. An increase in Mito-SOX red
ﬂuorescence is equated to mitochondria-derived ROS and by implica-
tion to mitochondrial production of O2•–. However, oxidation of the
redox probes (DCFH or Mito-SOX) resulting in enhanced ﬂuorescence
was observed in cancer cells due to metabolic reprogramming and drug
resistance. Unless the hydroxylated product of Mito-SOX oxidation can
be isolated and determined to be speciﬁc for O2•– (i.e., 2-OH-Mito-E+),
attributing increased red ﬂuorescence to mitochondrial O2•– or to
mtROS is incorrect!
E+ and structurally related analogs intercalate into DNA, and this
interaction increases the ﬂuorescence quantum yield. As a result, the
ﬂuorescence intensity is enhanced several-fold. The O2•–-speciﬁc pro-
duct, 2-OH-E+, also intercalates into DNA, increasing its ﬂuorescence
intensity [14,15]. Consequently, the ﬂuorescence derived from both E+
and 2-OH-E+ in the intracellular milieu is enhanced, making it diﬃcult
to interpret ﬂuorescence changes. Similar limitations apply to Mito-
SOX-derived products as well. Hartley, Murphy, and colleagues devel-
oped a new mitochondria-targeted O2•– probe, MitoNeoD, which is
Fig. 4. Lack of evidence for enhanced O2•– formation during tumorigenesis, meta-
bolic reprogramming, and drug resistance. In order to categorically state that O2•– is
formed during redox processes in tumor cells, it is essential to separate and detect the
corresponding O2•–-speciﬁc hydroxylated products from HE or Mito-SOX.
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diﬀerent from MitoSOX in that oxidation products derived from it do
not intercalate into DNA, thereby preventing ampliﬁcation of the red
ﬂuorescence due to the binding of the oxidation product to DNA [68].
MitoNeoD contains a reduced phenanthridinium moiety (modiﬁed to
prevent DNA intercalation) that reacts with O2•– to form the hydro-
xylated product, MitoNeoOH (Fig. 7), with the intermediacy of the
radical cation of MitoNeoD (formed from one-electron oxidation of the
probe). MitoNeoD contains a carbon-deuterium bond that inhibits some
pathways of nonspeciﬁc oxidation, thereby enhancing selectivity to-
ward O2•–. Finally, this probe possesses a triphenylphosphonium lipo-
philic cation that facilitates its uptake into mitochondria. It should be
emphasized, however, that even the deuterated probe is not selective
toward O2•–, and chromatographic analyses are required for speciﬁc
monitoring of the superoxide product (MitoNeoOH). MitoNeoD and
mito-paraquat (a mitochondria-targeted redox cycling agent) were ad-
ministered to mice, and the hydroxylated product, MitoNeoOH, was
Fig. 5. Mito-metformin induces increased O2•– and H2O2 formation in pancreatic cancer cells. O2•–-dependent oxidation of the HE probe (A) and H2O2-dependent oxidation of the
probe, o-MitoPhB(OH)2 (B) in MiaPaCa-2 cells treated for 24 h with Mito-Met10. (Obtained from Refs. [55,59]. Reprinted from Cancer Research, 76, G. Cheng, J. Zielonka, O. Ouari, M.
Lopez, D. McAllister, K. Boyle, C.S. Barrios, J.J. Weber, B.D. Johnson, M. Hardy, M.B. Dwinell, B. Kalyanaraman, Mitochondria-targeted analogs of metformin exhibit enhanced
antiproliferative and radiosensitizing eﬀects in pancreatic cancer cells, 3904-15, Copyright 2016, and from Interface Focus, 7, B. Kalyanaraman, G. Cheng, M. Hardy, O. Ouari, A. Sikora,
J. Zielonka, M. Dwinell, Mitochondria-targeted metformins: anti-tumor and redox signaling mechanisms, 20160109, Copyright 2017.).
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detected in the mitochondria isolated from the liver [68]. In the pre-
sence of mito-paraquat, the yield of the hydroxylated product was in-
creased, indicating the feasibility of detecting mitochondrial O2•– in in
vivo settings, when combined with LC-MS-based analyses of the ex-
tracts. Because of the deuterium isotope eﬀect and the bulky substituent
attached next to the amino group, it is likely that direct two-electron
oxidation of the probe to the E+-type product (MitoNeo cation) is
minimized as compared with HE or Mito-SOX [68].
6. Redox signaling, drug resistance, and metabolic
reprogramming in cancer cells: The role of mitochondrial ROS
As described previously, to better understand the role of ROS in
redox (reduction-oxidation) signaling and vice versa, it is important to
determine the identity of ROS (O2•–, H2O2, lipid, or protein oxidation
products). Previously, it was thought that ROS are always cytotoxic to
both cancer and normal cells. This has been the basis for cytotoxic
chemotherapy and radiation therapy, and the therapeutic goal has been
to increase the therapeutic window, enhancing tumor cytotoxicity and
decreasing toxicity normal cells. So, an eﬀective therapeutic strategy
was to inhibit ROS levels in normal cells through enhanced antioxidant
mechanisms. However, it is not as simple as it appears. Studies show
that ROS (H2O2 in particular) stimulate cancer cell proliferation
through modiﬁcations in the signaling pathways (e.g., PI3/Akt). On the
other hand, some studies report that antioxidant supplementation and
upregulation of antioxidant pathways actually enhanced tumor survival
by decreasing ROS cytotoxicity [69,70]. A major limitation of the newly
proposed role is that there is very little quantitative information on ROS
(modest and high levels) and their eﬀect on cancer cell proliferation/
cancer cell apoptosis. As reported previously, ROS formation and me-
tabolic changes are intertwined in cancer cells [1]. The redox status of
various cancer cells appears to be dependent on the metabolic
reprogramming that occurs during tumorigenesis, progression, and
metastasis of cancer cells. Metabolic reprogramming also induces en-
dogenous antioxidant machinery [71]. Increased detoxiﬁcation of ROS
has also been shown to promote tumorigenesis [72]. Furthermore, low
levels of ROS activate signaling pathways for cell proliferation and
survival [73]. Thus, it is diﬃcult to predict cancer cell response to ROS
modulation based on in vitro cell culture studies. With radiation
therapy, however, tumors are irradiated using a focused X-ray beam,
and the tumor cell killing is enhanced and the damage to collateral
tissue is minimized. Radiation therapy induces ROS (e.g., hydroxyl ra-
dical)-mediated DNA damage in tumor cells. However, cancer tissues
are more hypoxic than normal tissues, so the lack of oxygen is one of
the major limitations of radiation therapy.
Increased ROS formation and metabolic reprogramming were
shown to occur in cis-platin resistant cells [74,75]. The resistance to
antitumor drugs is a major impediment in chemotherapy [76,77].
Generally, widely used antitumor drugs like cis-platin elicit positive
response in lung cancer patients, but with continued use, the patients
develop resistance to cis-platin therapy and this treatment fails. Most
chemotherapeutic drugs are subjected to chemoresistance. Studies
using cis-platin-resistant cell lines derived from patients who failed cis-
platin chemotherapy revealed metabolic reprogramming [78]. These
resistant cells relied exclusively on oxidative metabolism and exhibit
increased OXPHOS (mitochondrial respiration) as determined by using
the Agilent Seahorse Extracellular Flux Analyzer [79]. However, the
signaling pathway responsible for enhanced OXPHOS in cis-platin-re-
sistant lung cancer cells was not determined.
As described earlier, increased ﬂuorescence due to using redox dyes
simply points to their enhanced oxidation; it does not provide evidence
in support of enhanced ROS (O2•–, H2O2, or lipid hydroperoxides) for-
mation. Although ROS detection and identiﬁcation remain question-
able, the investigators report a novel role for the drug riluzole's ability
to counteract cis-platin's resistance in lung cancer cells using the oxi-
dation of redox probes [75].
7. Oxidative phosphorylation-inhibiting drugs: Mitochondria-
targeted agents and antiproliferative eﬀects
Cancer cells use multiple metabolic pathways to acquire nutrients to
support their ever-increasing energetic needs. These include glycolysis,
glutaminolysis, and fatty acid oxidation. Treatment with antiglycolytic
drugs induces a compensatory increase in OXPHOS. In addition, in-
hibitors of kinase drugs (which often decrease glycolysis) enhance drug
resistance and the OXPHOS mechanism [80]. Cancer-cell-speciﬁc OX-
PHOS inhibitors are needed to counteract this compensatory response,
and currently available mitochondrial inhibitors are not very selective.
Cancer cells expressing oncogenic mutations in isocitrate dehy-
drogenase 1 and 2 (IDH1/2) showed increased dependence on oxidative
metabolism and are more sensitive to pharmacological inhibition of
OXPHOS. Mutant IDH1 cells exhibited higher sensitivity to electron
transport chain inhibition under hypoxia [81]. Results indicate that
IDH1 mutant cells are more dependent on complex I of the electron
transport chain and, consequently, are more susceptible to complex I
inhibition. Anti-OXPHOS drugs (mitochondria-targeted drugs) are
likely to exhibit enhanced antiproliferative eﬀects in mutant IDH1 cells
under hypoxic conditions.
Oxidative phosphorylation-inhibiting (anti-OXPHOS) drugs refer to
mitochondria-targeted or mitochondrial drugs that decrease the rate of
mitochondrial respiration through inhibition of electron transport chain
proteins such as complex I. Delocalized cations (e.g., rhodamine dye)
accumulate into mitochondria and inhibit mitochondrial respiration of
cancer cells. Molecules conjugated to the TPP+ moiety (e.g., Mito-Q,
Mito-CP, Mito-chromanol or Mito-vitamin-E, Mito-metformin; Fig. 8
and Fig. 9) accumulate preferentially into mitochondria driven by an
increased negative membrane potential [82–84]. Because of the in-
creased mitochondrial membrane potential in cancer cells as compared
Fig. 6. Dimeric product formed from one-electron oxidation of HE and analogs.
(Modiﬁed from Ref. [87]. Reprinted from Cell Biochemistry and Biophysics, Modiﬁed
Metformin as a More Potent Anticancer Drug: Mitochondrial Inhibition, Redox Signaling,
Antiproliferative Eﬀects and Future EPR Studies, 75, 2017, 311-7, B. Kalyanaraman, G.
Cheng, M. Hardy, O. Ouari, A. Sikora, J. Zielonka, M.B. Dwinell with permission of
Springer.).
Fig. 7. O2•–-speciﬁc and nonspeciﬁc oxidation products formed from the mi-
tochondrial superoxide probe, MitoNeoD. (Modiﬁed from Ref. [68]. Reprinted from
Cell Chemical Biology, 24, M.M. Shchepinova, A.G. Cairns, T.A. Prime, A. Logan, A.M.
James, A.R. Hall, S. Vidoni, S. Arndt, S.T. Caldwell, H.A. Prag, V.R. Pell, T. Krieg, J.F.
Mulvey, P. Yadav, J.N. Cobley, T.P. Bright, H.M. Senn, R.F. Anderson, M.P. Murphy, R.C.
Hartley, MitoNeoD: A Mitochondria-Targeted Superoxide Probe, 1285-98.e12, https://
doi.org/10.1016/j.chembiol.2017.08.003, https://creativecommons.org/licenses/by/4.
0/, Copyright 2017.).
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with normal, non-transformed cells, TPP+-containing molecules accu-
mulate in tumor mitochondria to a higher extent and longer than in
normal cell mitochondria. Both Mito-CP and Mito-vitamin E potently
and selectively inhibit complex I-mediated mitochondrial respiration or
oxygen consumption. These molecules are also retained in cancer cell
mitochondria more than in normal cell mitochondria and, therefore,
cause decreased mitochondrial respiration in cancer cells for a pro-
longed period of time. Although Mito-SOX and mito-boronates are used
as ROS probes, it should be noted that these probes contain a TPP+
moiety and can inhibit OXPHOS like other TPP+-containing mi-
tochondria-targeted compounds [67,85].
Metformin and Mito-metformin inhibit cancer cell proliferation
through the inhibition of complex I, ROS generation, activation of AMP-
activated protein kinase (AMPK), and inhibition of mTOR function.
Anti-OXPHOS drugs are diﬀerent from rapamycin, which directly
blocks mTOR leading to AMPK activation. Mito-metformin10 is the most
potent of all Mito-metformin analogs tested in inhibiting complex I-
mediated oxygen consumption [59]. The IC50 values for inhibiting
oxygen consumption decrease with increasing carbon–carbon side
chain length. Inhibition of pancreatic cancer cell proliferation measured
under these conditions follows the same pattern, pointing to the cau-
sative role of complex I inhibition in the antiproliferative eﬀects of
Mito-metformins.
8. Establishing the mechanism using the right control: An
example using a mitochondria-targeted nitroxide
Anti-OXPHOS drugs containing TPP+ typically stimulate ROS for-
mation in cancer cells [86,87]. At the same time, these drugs inhibit
cancer cell proliferation [84]. H2O2 generated by oncogene activation
enhanced tumor cell proliferation via stimulation of mitogen-activated
protein kinase (MAPK) [88], as discussed in a subsequent section. Mito-
CP containing the 10-carbon side chain is paradoxical in that it contains
a nitroxide group that can function as a superoxide dismutase (SOD)
mimetic while stimulating mitochondrial ROS through inhibition of
complex I. We had previously used Mito-CP to mimic mitochondrial
SOD activity and protect endothelial cells from oxidant-induced da-
mage [89]. Nitroxides such as carboxy proxyl (CP) and Tempol have
previously been used as SOD mimetics (like the SOD enzyme, CP cat-
alytically dismutates O2•– to H2O2 and O2) [90]. Mito-CP is a CP analog
that is synthesized by conjugating a TPP+ group to CP via an 11-carbon
alkyl chain (Fig. 9). Mito-CP protected endothelial cells from oxidative
injury induced by exposure to a steady ﬂux of H2O2 and lipid hydro-
peroxides [89]. Mito-CP prevented the inactivation of mitochondrial
aconitase (an endogenous marker of O2•– production) in endothelial
cells, and this eﬀect was attributed to dismutation of O2•– by Mito-CP.
The “untargeted” nitroxide, CP (as a control), did not protect against
endothelial cell damage or inactivation of aconitase.
In studies using cancer cells, Mito-CP was found to signiﬁcantly
inhibit cancer cell proliferation [91–95]. This ﬁnding supported the
view that mitochondria-generated O2•– plays a role in cancer cell pro-
liferation and that Mito-CP inhibits cell proliferation by removing O2•–.
In control experiments, an alkyl TPP+ and CP were used. This combi-
nation did not selectively inhibit cancer cell growth, suggesting that CP
(containing the nitroxide moiety) should be conjugated to TPP+ for
eﬃcacy.
More recently, a Mito-CP analog, Mito-CP-Ac, that contains an
acetamide group in place of the nitroxide of Mito-CP, was used [94].
The Mito-CP-Ac is nearly the same as Mito-CP except for the replace-
ment of the nitroxide group by an acetamide group (Fig. 9). Mito-CP-Ac
does not possess the O2•– scavenging ability so it was an ideal control
molecule. Mito-CP-Ac inhibited cancer cell proliferation as eﬀectively
as did Mito-CP. Mito-CP-Ac was not metabolized to Mito-CP in-
tracellularly [94]. This ﬁnding challenged our original interpretation
that Mito-CP inhibited cancer cell proliferation by dismutating O2•–. We
subsequently revised our original proposal that the antiproliferative
eﬀect of Mito-CP is caused by its ability to dismutate O2•– or scavenge
ROS and that a likely mechanism for the antiproliferative eﬀects of
Mito-CP and Mito-CP-Ac in cancer cells might be linked to their abilities
to induce mitochondrial stress and activate redox signaling mechanisms
rather than the SOD mechanism [94].
The results obtained from using both Mito-CP and Mito-CP-Ac have
implications in understanding the eﬀects of other mitochondria-tar-
geted nitroxides including Mito-Tempol and Mito-Tempo [96]. Tempol,
amino Tempol, and other Tempol/Tempo analogs are six-membered
nitroxides whereas the CP family consists of a ﬁve-membered nitroxide.
Mitochondria-targeted Tempo or Tempol analogs synthesized via at-
tachment to the TPP+ moiety using linkers such as varying alkyl chain
lengths are typically used to test the involvement of mitochondrial O2•–
(also referred to as MROS) and O2•–-induced redox signaling in cancer
cells [65]. It is also likely that Mito-Tempo is acting as a chain-breaking
antioxidant via its hydroxylamine form. On the basis of Mito-CP and
Mito-CP-Ac results in cancer cells, it is clear that one has to use the most
appropriate control (i.e., Mito-Tempo-Ac) (Fig. 10) to absolutely verify
the role of O2•–. Mito-Tempo-Ac lacks the nitroxide moiety needed to
Fig. 8. Some examples of TPP+-based positively charged anticancer agents. Note
that it is critical to clearly deﬁne the complete structure indicating the side chain length of
mitochondria-targeted TPP+-based compounds. (Modiﬁed from Ref. [84]. Adapted with
permission from J. Zielonka, J. Joseph, A. Sikora, M. Hardy, O. Ouari, J. Vasquez-Vivar,
G. Cheng, M. Lopez, B. Kalyanaraman, Mitochondria-Targeted Triphenylphosphonium-
Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic
Applications, Chemical Reviews 117(15) (2017) 10043-120. Copyright 2017 American
Chemical Society.).
Fig. 9. Chemical structures of Mito-CP and its redox inactive analog, Mito-CP-acetamide.
Fig. 10. Chemical structures of Mito-Tempo and Mito-Tempo acetamide.
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dismutate O2•– but will accumulate in mitochondria stimulating other
stress-induced redox signaling mechanisms (such as Mito-Tempol) in
cancer cells.
Investigators recently showed that lipid electrophiles generated
endogenously during the inﬂammatory response form adducts with
mitochondrial proteins [97]. In the presence of Mito-Tempo, a marked
decrease in lipid electrophile adduction to proteins was observed. It was
concluded that O2•– generated in the mitochondrial electron transport
chain is a precursor responsible for lipid electrophile generation. This is
indeed a novel mechanism that should be further corroborated using a
more appropriate control (e.g., Mito-Tempo-Ac) that is similar to Mito-
Tempo but devoid of the nitroxide moiety and its superoxide dis-
mutating ability.
9. Peroxiredoxin enzymes: A family of thiol peroxidases
Peroxiredoxins are a family of redox sensing thiol peroxidase en-
zymes that detoxify H2O2 in combination with thioredoxin (Trx) and
thioredoxin reductase (TrxR). Mitochondria typically contain two per-
oxiredoxin isoenzymes (Prx3 and Prx5). Although low molecular
weight thiols such as cysteine and glutathione and redox-regulated
proteins with low pKa cysteines react with H2O2 rather slowly (k =
1–10 M−1 s−1), protein thiol peroxidases (e.g., peroxiredoxins and
glutathione peroxidases) react rapidly with H2O2 (k =
105–108 M−1 s−1) [98,99]. The antioxidant potency of peroxiredoxins
is vastly enhanced due to redox-coupled processes with the Trx/TrxR
system (Fig. 11). Prx3 is present in mitochondria at a fairly high con-
centration (60 μM) and reacts with H2O2 very rapidly (k =
107 M−1 s−1) compared with catalase. Although the enzyme glu-
tathione peroxidase-1 (GPx1) also reacts with H2O2 rapidly (k = 6 ×
107 M−1 s−1), its concentration in mitochondria is relatively low (~
2 μM). Thus, Prx3 is the major H2O2 detoxifying enzyme (~ 90% of
H2O2) in mitochondria [100].
In the ﬁrst step of the reaction, the cysteine residue of Prx3 reacts
with H2O2 to form a protein sulfenic acid (Cys-SOH) that combines with
another Prx3 cysteine to form an intermolecular disulﬁde bond. In the
second step, the oxidized Prx3 is converted back to its reduced state by
Trx2 and TrxR2. In the presence of excess H2O2, Prx3 cysteine sulfenic
acid undergoes hyperoxidation to form an inactive Prx3 cysteine sul-
fonic acid (Cys-SOOH) [101,102].
Because of its relative stability and selective reactivity with cellular
components, intracellularly generated H2O2 may diﬀuse over large
distances (several microns) and participate in signal transduction. Thus,
any involvement of ROS (H2O2 in particular) in tumorigenesis needs to
be considered in the context of the presence and reactivity of peroxir-
edoxins and glutathione peroxidases and other redox partners involved
(Fig. 11). Emerging studies in cancer are recognizing the role of tran-
scription factors such as STAT3 in the redox signaling pathway and cell
proliferation [103], as discussed in a subsequent section.
10. How does oxidative stress regulate cell signaling and
proliferation of tumor cells?
One of the mechanisms by which tumor cells maintain non-cyto-
toxic levels of ROS is through upregulation of antioxidant enzyme ex-
pression (e.g., controlled via the nuclear factor erythroid 2 [Nrf2]
pathway) and reductive cofactors (NADPH and GSH). At nontoxic le-
vels, H2O2 can regulate cancer cell signaling through oxidation of cy-
steine residues. For example, H2O2 inactivates the PTEN molecule, a
tumor suppressor, by oxidizing the active site cysteine to a disulﬁde,
which prevents inactivation of the PI3 pathway [104]. Endogenous
oncogene-mediated generation of ROS (H2O2 in particular) enhances
tumor cell proliferation by stimulating MAPK/extracellular signal
regulated kinase (ERK) pathways by inhibiting the action of MAPK
phosphatases (via oxidation of the active site cysteines). ROS therefore
can modulate/regulate cellular signaling factors. For example, ROS
generated from mitochondria are required for KRAS lung cancer growth
resulting from MAPK/ERK activation [95]. Increased ROS can also ac-
tivate transcription factors like the nuclear factor kappa B (NF-κB),
which enhances cancer cell proliferation [105].
Alternatively, ROS levels can be increased to a cytotoxic level in
breast cancer cells and breast cancer models by using inhibitors of GSH
and Trx pathways. Inhibiting the antioxidant enzyme, glutathione
peroxidase, through suppression of fumarate in the Krebs cycle, en-
hanced ROS levels and cancer cell growth [106]. As a result of the
paradoxical role of ROS in cancer cells, both pro- and antioxidant ap-
proaches have shown tumor enhancing and tumor regressing eﬀects
[107]. Similar to autophagy and mitophagy, which have been shown to
be both pro- and antitumorigenic, mitochondria-generated ROS can
exert tumor promoting and tumor suppressing eﬀects. These are also
dependent on tumor stage. The good and bad aspects of ROS have
previously been addressed in relation to aging [108]. The signaling
aspects of ROS (induction of host defense pathway via a hormetic me-
chanism) are considered to be good/pro-survival, whereas ROS-induced
oxidative damage to DNA, proteins, and lipids is considered bad/pro-
death. Because antioxidants could inhibit both the good and bad aspects
of ROS activities, the clinical interventions using antioxidants could be
problematic in the absence of the right balance [109]. It is likely that
we face the same type of ROS conundrum in cancer biology research as
well. In addition, reports suggest that a subset of melanoma tumor cells
exhibit metabolic reprogramming heterogeneity with diﬀerent bioe-
nergetic and ROS detoxiﬁcation capabilities [110]. Clearly, a more
detailed understanding of how cancer cells reprogram metabolism to
combat oxidative damage is vital prior to clinical intervention with
antioxidants.
Recent literature suggests that reprogramming of cellular metabo-
lism plays a crucial role in tumorigenesis [111]. Cancer cells acquire
energy to proliferate through metabolic reprogramming as follows: al-
tered glucose utilization, glutamine addiction or glutaminolysis, and
lipid metabolism. Modulating the pathway generating cellular re-
ductants (NADPH, GSH) can aﬀect ROS formation/scavenging and tu-
morigenesis. Elevation of glutamine utilization (increased catabolism of
glutamine, glutamine addiction) is one of the hallmarks of metabolic
reprogramming in tumors. Glutamine is converted to glutamate by
glutaminase (also upregulated by transcription factor cmyc) and glu-
tamate is oxidized to α-ketoglutarate that enters into the TCA cycle.
Transaminases use α-ketoglutarate to support redox homeostasis.
Sirtuin 3 (SIRT3) is a major deacetylase in mitochondria that is also
considered as a ROS mitigator in cells. SIRT3 targets MnSOD and iso-
citrate dehydrogenases. Reports suggest that SIRT3 could have a dual
role in cancer, both as an oncogene and tumor suppressor [112]. Tumor
suppressors, such as p53, regulate glutaminase, an enzyme involved in
the formation of glutamate required for synthesis of glutathione
[113,114]. Loss of p53 results in increased levels of ROS and oxidative
damage in cancer cells [115].
PPARγ coactivator-1α (PGC1α) is a transcription factor that is
Fig. 11. Peroxiredoxin pathway of H2O2 metabolism. (Modiﬁed from Ref. [103].
Reprinted by permission from Macmillan Publishers Ltd: Nature Chemical Biology, M.C.
Sobotta, W. Liou, S. Stöcker, D. Talwar, M. Oehler, T. Ruppert, A.N.D. Scharf, T.P. Dick,
Peroxiredoxin-2 and STAT3 form a redox relay for H2O2 signaling, Nature Chemical
Biology 11(1) (2015) 64–70, copyright 2015.).
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involved in mitochondrial biogenesis, oxidative metabolism, and me-
tabolic reprogramming [116,117]. The role of PGC1α in tumorigenesis,
progression, and metastasis appears to be dependent on cancer type,
reﬂecting the inﬂuence of microenvironment (nutrient status and tissue
hypoxia) and genetic perturbations on the metabolic state of cancer
cells [118]. PGC1α exhibits both pro- and antitumor function in cancer
cells [119,120]. PGC1α increases mitochondrial respiration and bio-
genesis and helps cancer cells cope with enhanced metabolic and oxi-
dative stress through enhanced expression of ROS detoxiﬁcation en-
zymes and increased resistance to cancer therapy. PGC1α reportedly
decreases mitochondria-generated ROS [110]. Inhibiting PGC1α ac-
tivity or its expression has been shown to enhance ROS levels and in-
crease stabilization of the HIF1α protein, inducing a switch in meta-
bolism from OXPHOS to glycolysis [121]. PGC1α-positive melanoma
cells are more sensitive to disruption of mitochondrial respiration as
they depend on PGC1α for survival. Conversely, PGC1α-negative mel-
anoma cells with compromised antioxidant enzyme activity are more
susceptible to ROS-generating drugs and oxidative stress (Fig. 12).
The role of PGC1α in tumorigenesis is paradoxical and is dependent
on the type of cancer and its phenotype. PGC1α is reported to be pro-
and antitumorigenic. In contrast with melanoma cells, PGC1α sup-
presses prostate cancer metastasis and inhibits renal cell carcinoma
[117]. PGC1α overexpression impaired renal cancer cell growth by
enhancing ROS and oxidative stress. PGC1α also enhances the sus-
ceptibility of renal carcinoma cells, RCC4, to cytotoxic therapy (radia-
tion or doxorubicin) [121]. PGC1α enhanced mitochondrial content,
ROS formation, and oxidative damage leading to impaired tumor
growth [117,120]. Thus, measurement of PGC1α levels in tumor sub-
sets could help design appropriate anticancer drug therapy.
11. Do antioxidants enhance tumorigenesis and tumor
metastasis?
It is well known that ROS (hydroxyl radical, H2O2, and O2•– and
redox metal ions) can cause oncogenic mutations, and that treatment
with antioxidants and antioxidant enzymes (ebselen, catalase, SOD, and
SOD mimetics) inhibits the initiation and progression of some cancers
[122]. However, several studies report the opposite results. The cancer
biology ﬁeld shares the same concerns (as the cardiovascular ﬁeld) with
respect to antioxidant supplementation. Antioxidant supplementation
shows both beneﬁcial and deleterious eﬀects [123]. Of signiﬁcance was
the report demonstrating that antioxidant supplementation enhanced
lung cancer progression in mouse models of BRAF- and KRAS-induced
lung cancer. Two functionally diﬀerent compounds were used to test
the eﬀect of antioxidants on cancer: a lipid-soluble vitamin E (a bona
ﬁde lipid peroxidation inhibitor and a chain-breaking antioxidant that
terminates lipid peroxidation by scavenging ROS, lipid peroxyl radical)
and a water-soluble drug, N-acetylcysteine (NAC), that is not a
conventional antioxidant that reacts with ROS (O2•– and H2O2) at an
appreciable rate compared with the endogenous antioxidant enzymes.
However, NAC supplementation enhances the intracellular glutathione
levels that will decrease ROS levels through enhanced activity of anti-
oxidant enzymes. Despite limitations and problems in data interpreta-
tion with respect to ROS, this study is clearly provocative and questions
the indiscriminate supplementation of antioxidants such as isoﬂavones,
beta-carotenes, vitamin E, and NAC for suppressing tumor progression
[124]. Oxidative stress was reported to inhibit melanoma metastasis
[125]. Supplementation with antioxidants (NAC) promoted metastasis
by inhibiting oxidative stress.
The paradoxical behavior of ROS and antioxidants in cancer is not
unique in that similar eﬀects have been observed in other ﬁelds of re-
search including aging and cardiovascular diseases [108,126]. Several
years ago, it was shown that beta-carotene may have an adverse eﬀect
on the incidence of lung cancer and cardiovascular disease in a clinical
trial involving smokers [127]. Although the pro-oxidant mechanism of
action is not known, this study pointed out the inadequacy in our un-
derstanding of the pro- and antioxidant mechanisms of action in hu-
mans.
12. Therapeutic targeting of signaling pathways
ROS-mediated signaling pathways, elevated in many tumors, are
involved in cell growth and proliferation, diﬀerentiation, survival, and
metabolism. ROS, in particular H2O2, may act as second messengers in
cell signaling. H2O2 regulates protein activity via direct or indirect re-
versible oxidation of protein tyrosine phosphatases, protein and re-
ceptor tyrosine kinases, and transcription factors [128,129].
12.1. PI3/Akt signaling pathway
One of the hallmarks of cancer is the hyperactivation of the phos-
phoinositide 3-kinase (PI3K)-Akt signaling pathway and is an attractive
target for antitumor therapy. Akt is a proto-oncogene that is activated
in many cancers. In addition to growth factors, ROS (possibly H2O2) are
involved in the mechanisms responsible for PI3K signaling [130]. The
activated PI3K subsequently phosphorylates phosphatidylinositol-4,5-
biphosphate (PIP2) to phosphatidylinositol-3,4,5-triphosphate (PIP3)
that acts as a signaling molecule to recruit phosphoinositide-dependent
kinase-1 (PDK1) and protein kinase B (PKB, also known as Akt). The
tumor suppressor phosphatase, PTEN, downregulates the PI3K/Akt
signaling pathway by dephosphorylation of PIP3 back to PIP2 [131].
ROS (importantly H2O2) oxidize the cysteinyl group in PTEN molecules
such that PTEN is inactivated, thereby resulting in activation of the
PI3K/Akt signaling pathway and tumor progression. Akt is hyper-
activated by other mechanisms as well, and is involved in the regulation
of multiple cellular activities. Akt inhibits the forkhead box O (FOXO)
transcription factor and subsequently regulates apoptosis, leading to
enhanced tumor growth [132,133].
12.2. MAPK/Erk1/2 pathway
ROS such as H2O2 can oxidatively modify the cysteinyl residue of
proteins (e.g., protein tyrosine phosphatases [PTPs], protein tyrosine
kinases [PTKs], and protein kinase C [PKC]) and subsequently activate
downstream kinase cascade (e.g., MAPKs). One of the most extensively
studied MAPK pathway is the ERK1/2 signaling pathway. ERK1/2 ac-
tivation is linked to regulation of cancer cell survival, proliferation, and
metastasis [134]. Mutations in genes encoding RAS and RAF modulate
cancer development through the RAS-RAF-MEK-ERK kinases axis.
12.3. AMPK/mTOR
Mitochondria-targeted therapeutics (e.g., Mito-metformin) activate
AMPK [59]. AMPK is a master energy sensor within the cell. AMPK
Fig. 12. PGC1α regulates mitochondrial biogenesis and oxidative stress in mela-
noma cells. (Modiﬁed from Ref. [110]. Reprinted from Cancer Cell, 23, F. Vazquez, J.H.
Lim, H. Chim, K. Bhalla, G. Girnun, K. Pierce, C.B. Clish, S.R. Granter, H.R. Widlund, B.M.
Spiegelman, P. Puigserver, PGC1alpha expression deﬁnes a subset of human melanoma
tumors with increased mitochondrial capacity and resistance to oxidative stress, 287–301,
Copyright 2013, with permission from Elsevier.).
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activation is initiated by the enhanced intracellular ratio of AMP to
ATP. AMPK activation results in the upregulation of ATP-generating
pathways and decreased ATP-consuming pathways. AMPK regulates the
redox state by mitigating the NADPH depletion that occurs via in-
creased fatty acid oxidation and decreased fatty acid synthesis. The
relationship between AMPK activation and cancer cell proliferation
became evident in light of the protective eﬀects induced by AMPK in-
hibitors. Inhibiting AMPK signaling by dorsomorphin (compound C)
reversed the antiproliferative eﬀect of mitochondria-targeted ther-
apeutics such as Mito-metformin [59]. Mito-metformin stimulated O2•–
and H2O2 formation in pancreatic cancer cells (Fig. 5) [55,59,87]. Mito-
metformin-induced inhibition of complex I was thought to be re-
sponsible for formation of O2•– and H2O2. We proposed that H2O2 de-
rived from complex I inhibition was responsible for the AMPK activa-
tion and mTOR inhibition that are related to the inhibition of
proliferation (Fig. 13). A recent report also suggested that mitochon-
drial ROS were responsible for the AMPK activation that was linked to
oxidation of calmodulin kinase II [135]. Inhibiting calmodulin kinase II
suppressed AMPK activation. Additional experiments using AMPK
knockout cells and xenografts are needed to gain a complete under-
standing of the role of ROS in the AMPK signaling mechanism.
12.4. Signal transducer and activator of transcription: STAT3/
peroxiredoxin and transmission of H2O2 signaling via redox relay
As discussed above, thiol peroxidase, peroxiredoxin, eﬀectively and
rapidly scavenges H2O2 in both the cytosolic and mitochondrial com-
partments in cells. Recently, investigators reported an additional novel
mechanism for the redox activity of thiol peroxidase, peroxiredoxin-2
(Prx2), in that Prx2 acts as a signal transductor and a redox regulator
(Fig. 14). Rather than directly oxidizing thiols in STAT3, H2O2 rapidly
reacts with Prx2 cysteinyl thiol to form an oxidized Prx2 (Prx2 sulfenic
acid and disulﬁde). The oxidized Prx2 forms a disulﬁde exchange in-
termediate with STAT3, leading to oxidation of the STAT3 thiols and
aﬀecting its transcriptional activity. Oxidized STAT3 can be reduced
back to its active form by the Trx/TrxR system, using NADPH as the
ultimate electron donor (Fig. 14). This model shows how redox reg-
ulating proteins may transmit oxidizing and reducing equivalents from
H2O2 and NADPH, respectively, to control the activity of redox-sensi-
tive proteins. STAT-dependent regulation of ROS and oxidative meta-
bolism in normal and cancer cells is an emerging area of research
[101,103].
12.5. Keap1 mutations, Nrf2-targeted gene activation, ROS, and glutamine
uptake in tumor cells
Tumor cells are metabolically hyperactive during tumorigenesis in
order to meet and sustain their energy and building-blocks require-
ments for enhanced growth. Enhanced metabolism results in ROS
generation during tumorigenesis [136]. Tumor cells activate the Nrf2
pathway via metabolic reprogramming to stimulate the expression of
antioxidant enzymes, leading to decreased ROS levels [137]. Glu-
tathione synthesis was elevated in Keap1 or Nrf2-mutant lung cancers
through enhanced glutaminolysis.
The Keap1 (Kelch-like ECH-associated protein 1) gene is one of the
most frequently mutated genes in KRAS-mutant lung adenocarcinoma.
It is estimated that approximately 20% of KRAS-mutant lung cancer
cells carry the mutated Keap1 gene. Keap1 is a negative regulator of
Nrf2, the master transcriptional regulator of the endogenous anti-
oxidant response, and thus is critical for maintaining the redox home-
ostasis in cells.
Keap1-Nrf2 is a redox regulating system that plays a critical role in
oxidative stress and cytoprotection. Under basal conditions or non-
oxidative stress conditions, the Keap1/Nrf2 complex is constantly de-
graded by the ubiquitin-proteasome pathway. Increased levels of ROS
or electrophiles (4-HNE formed from oxidized lipids) result in mod-
iﬁcation of the cysteinyl residues of Keap1 and stop the negative reg-
ulation of Nrf2 by Keap1. Consequently, Nrf2 is stabilized and migrates
to the nucleus and activates the expression of target genes that include
antioxidative stress genes (heme oxygenase 1, peroxiredoxin 1,
MnSOD), detoxifying enzyme genes (NADPH quinone oxidoreductase,
glutathione S-transferases), and ABC transporter genes (Fig. 15).
Nrf2 has a dual mechanism of action in cancer therapies, exhibiting
chemotherapy and radiotherapy resistance and proliferative capacity,
and promoting host defense against cancer cells. Nrf2 protects against
oxidative stress in normal cells, and Nrf2 activation in cancer cells in-
duces drug and radiation resistance. Patients bearing Nrf2-activated
tumors exhibit poor prognoses. Activation of Nrf2 is associated with
tumor resistance to anticancer drugs via detoxiﬁcation of ROS and
electrophiles induced by the drugs. Inhibitors of the Keap1-Nrf2
pathway enhanced chemosensitivity in lung cancer cells [138].
12.6. ROS and autophagy
Autophagy or “self-eating” is a highly regulated process of removing
modiﬁed or damaged intracellular proteins that are presumably re-
quired to maintain redox homeostasis [139]. Its functional role (cyto-
protective or cytotoxic) in normal and cancer cells is diﬀerent and
context-dependent [140]. Enhancement or mitigation of autophagy in
tumorigenesis depends on the tissue, the stage, and the type of tumor
[141]. It is becoming more evident that ROS generated from mi-
tochondria (and probably from Nox activation) and the resulting oxi-
dative stress is responsible for increasing autophagic ﬂux, which, in
Fig. 13. Mito-metformin and activation of AMPK: Potential signaling role of H2O2.
(Obtained from Ref. [59]. Reprinted from Cancer Research, 76, G. Cheng, J. Zielonka, O.
Ouari, M. Lopez, D. McAllister, K. Boyle, C.S. Barrios, J.J. Weber, B.D. Johnson, M. Hardy,
M.B. Dwinell, B. Kalyanaraman, Mitochondria-targeted analogs of metformin exhibit
enhanced antiproliferative and radiosensitizing eﬀects in pancreatic cancer cells, 3904-
15, Copyright 2016.).
Fig. 14. Redox signaling of H2O2 via peroxiredoxin/Trx redox relay including
STAT3 transcription factor. (Obtained from Ref. [103]. Reprinted by permission from
Macmillan Publishers Ltd: Nature Chemical Biology, M.C. Sobotta, W. Liou, S. Stöcker, D.
Talwar, M. Oehler, T. Ruppert, A.N.D. Scharf, T.P. Dick, Peroxiredoxin-2 and STAT3 form
a redox relay for H2O2 signaling, Nature Chemical Biology 11(1) (2015) 64–70, copyright
2015.).
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turn, decreases ROS levels. Thus, autophagy can play an antitumoral
and protumoral role during cancer development [142]. ROS were
proposed to serve as intracellular messengers to regulate autophago-
some formation. During the initiation phase, where ROS-induced DNA
damage is the key event, autophagy plays an antitumoral role. How-
ever, during the propagation, progression, and metastatic phases of
cancer development, autophagy may play a protumoral role because of
decreased ROS-mediated oxidative stress and increased production of
nutrients provided by autophagic activation.
Starvation or nutrient deprivation triggers autophagy.
Pharmacologically, mitochondria-targeted drugs can promote autop-
hagy through stimulation of bioenergetic stress, increased ROS forma-
tion, AMPK activation, and mTOR inhibition [143]. Alternatively, en-
hanced PI3K-1/Akt and MAPK/ERK1/2 signaling activate mTOR and
regulate autophagy [144]. It is clear that the balance between ROS
levels and ROS-induced autophagy is critical for tumor progression or
regression. Antioxidants and their paradoxical eﬀects in cancer may be
linked to the cytoprotective or cytotoxic mechanisms of autophagy.
Antimalarial drugs, chloroquine and hydroxychloroquine, inhibit
autophagy and are undergoing clinical trials as antitumor drugs [145].
However, reports also indicate the potentially deleterious adverse ef-
fects of inhibiting autophagy in kidney and other organs [146]. Com-
bining chloroquine with the standard-of-care chemotherapies (cis-platin
and doxorubicin) was reported to exacerbate nephrotoxicity and pos-
sibly cardiotoxicity [147].
12.7. ROS and the tumor microenvironment
T cells in the tumor microenvironment (TME) are eﬀective in re-
cognizing and killing malignant cells. The TME, especially in pancreatic
tumors, has been shown to be immunosuppressive, and granulocytic
myeloid-derived suppressor cells (MDSC) have been identiﬁed as sup-
pressors of the immunoresponse to tumor cells [148]. Previously, Corzo
et al. showed that ROS generated from Nox2 were responsible for T cell
inactivation or suppression by granulocytic MDSC [149]. The defective
T cell reactivity against the tumor is a prominent feature of tumor
suppressive microenvironment in PDAC. Because MDSC deﬁcient in
Nox2 do not suppress T cell reactivity, it was rationalized that Nox2-
generated ROS caused the inactivation of T cells. Inhibiting Nox sig-
naling using small molecular weight compounds could potentially en-
hance tumor-speciﬁc T cell responses.
The role of Nrf2 in the tumor microenvironment is intriguing. MDSC
consisting of macrophages, dendritic cells, and neutrophils support
tumor development and metastasis by inhibiting innate and adaptive
immunity. ROS generated by MDSC in the tumor microenvironment
facilitate immunosuppression by MDSC. Nrf2 activation regulates the
immunosuppressive action of MDSC by modulating ROS levels
[150,151].
13. In vivo measurements of ROS in tumor tissues
Typically, either protein carbonyls or protein tyrosyl nitrated pro-
ducts are used as in vivo markers of oxidant (ROS/RNS) formation
[152]. DMPO has been used to trap protein radicals, and an antibody to
DMPO has been used to detect this adduct using an immunospin-trap-
ping method [153]. Some other newly developed probes and techniques
for assessing in vivo oxidants are described below.
13.1. MitoB
MitoB (a boronate probe attached to a TPP+ moiety) was used to
detect mitochondria-generated H2O2 in a living organism [30,31]. This
probe reacts stoichiometrically with H2O2 to form a diagnostic exo-
marker, MitoP. One of the advantages of the TPP+ cation is that the
positive charge enhances the sensitivity of detection (pmol/g levels) by
LC-MS. The MitoP/MitoB ratio was used as a measure of H2O2 gener-
ated within mitochondria. The investigators used a meta-substituted
boronate probe (meta-MitoB). Because peroxynitrite reacts with this
probe a million-fold faster than H2O2 (yielding the same product
[MitoP]), it is essential to use a probe that will distinguish between the
two species. As indicated previously, in the presence of peroxynitrite,
ortho-MitoB will form a cyclized product (not possible with meta-
MitoB) that can be used as a speciﬁc exomarker for ONOO– (Fig. 2)
[28,32,33]. Absence of formation of this minor product would indicate
that MitoP is formed in peroxynitrite-independent process, most likely
by H2O2.
13.2. Mito-NeoD
Recently, Hartley, Murphy, and colleagues synthesized a phenan-
thridinium-based mitochondria-targeted superoxide probe, MitoNeoD,
that is more robust than the existing probes for detecting O2•– formed in
animals [68]. As discussed, the chemistry between MitoNeoD and O2•–
and other oxidants is similar to that described for HE and Mito-SOX
(Fig. 7) [59]. Reaction with O2•– results in the formation of MitoNeoOH
from MitoNeoD as a diagnostic marker product. In contrast to HE and
Mito-SOX, MitoNeoD was shown to be more robust because of the
presence of bulky neopentyl groups and incorporation of deuterium at
carbon-6 position [68]. These modiﬁcations decrease the extent of
nonspeciﬁc oxidation to the E+ analog product (MitoNeo) and its DNA
Fig. 15. Schematic of the Keap1–Nrf2–ARE pathway.
(Modiﬁed from Ref. [128]. Reprinted from Oncotarget, 8, X. Gao,
B. Schottker, Reduction-oxidation pathways involved in cancer
development: a systematic review of literature reviews, 51888-
906, copyright 2017.).
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intercalation. MitoNeoOH, the superoxide-speciﬁc product, is typically
detected by LC-MS/MS (after extraction from the tissue) relative to
deuterated internal standards [68].
13.3. Low-temperature EPR
Electron paramagnetic resonance (EPR) spectroscopy detects un-
paired electrons, including those in free radicals and in many electronic
states of transition ions (e.g., FeIII, CuII MnII/III/IV) and in metal clusters
(e.g., [2Fe2S]+, [3Fe4S]0/+, [4Fe4S]+). EPR is often diagnostic for
individual paramagnetic species, and 12–16 of the approximately 20
signals expected from mitochondria can be assigned depending on the
tissue and redox status [154]. EPR is also quantitative and amounts of
species in the paramagnetic state can be estimated by computer ﬁtting.
EPR of mitochondrial redox centers requires cryogenic temperatures
(5–40 K). At such low temperatures, unpaired electrons remain free to
migrate between redox centers with appreciable exchange interactions
and adopt statistical distributions according to the centers’ midpoint
potentials. However, diﬀusion and active transport of molecules ceases.
Therefore, low-temperature EPR of ﬂash-frozen intact tissue or cell
samples provides a snapshot of the redox status of the various mi-
tochondrial respiratory chain complexes at the time of freezing, and
reports on the midpoint potentials of the individual redox centers and
the integrity of their intramolecular electron transfer pathways. EPR
also reports on oxidative stress history, most conveniently through in-
terrogation of the oxidative partial disassembly of the mitochondrial
aconitase EPR-silent [4Fe4S]2+ to the characteristically EPR-active
[3Fe4S]+ center [155,156]. The use of low-temperature EPR in mi-
tochondrial diseases [154], neurodegeneration and neuroprotection
[6,157], and chromium toxicity [155] has been reported, and the po-
tential for use in tumor investigation appears high.
13.4. Complexes I and II EPR signals as redox status markers
Complexes I and II together generally exhibit up to seven signals due
to reduced FeS clusters (complex I: N1b, N2, N3, and N4; complex II:
S1, S2, and Rieske cluster) and an additional signal due to oxidized
complex II S3. The “g2” resonance positions of each of the reduced
[2Fe2S] and [4Fe4S] clusters overlap considerably, giving rise to an
intense and characteristic EPR line at g = 1.94 in most tissues under
normal physiological conditions. Reduced intensity of this signal in-
dicates a global increase in the redox potential. Two centers, N3 and
N4, have very low midpoint potentials, close to the NADH/NAD+
couple, and exhibit weak but well-separated respective g3 EPR re-
sonances with g<1.9, i.e., well upﬁeld of the other signals. The relative
intensities of the N3 and N4 signals and the g = 1.94 signal are,
therefore, very sensitive markers for subtle changes in redox status.
Computer ﬁtting can reliably separate the complex II signals S1 and S2
from the complex I signals, though not from each other; this provides a
way to distinguish global from local phenomena. The signal intensities
of the reduced clusters may also be compared with the intensity of the
oxidized S3 signal. The S3 signal overlaps substantially with the aco-
nitase [3Fe4S]+ signal but is readily diﬀerentiated by a markedly dif-
ferent temperature dependence. Thus, a wealth of information on redox
status is available from which various inferences can be made, though
complementary techniques may well be required to elucidate the un-
derlying mechanisms of dysfunction [154].
13.5. Aconitase inactivation: EPR detectable biomarker of mitochondrial
oxidation
Aconitase inactivation is used as an EPR marker of oxidative stress
as O2•– produced from mitochondrial electron transport chain dys-
function reacts with the iron-sulfur centers. Aconitase is converted from
the enzymatically active, EPR-silent, [4Fe4S]2+-containing form to the
enzymatically inactive, but EPR-active, [3Fe4S]+ form [156,158]
(Fig. 16). The EPR signals from the distinct mitochondrial and cytosolic
forms of aconitase are easily distinguishable with the isolated enzymes
[159] but may be diﬃcult to diﬀerentiate in the complex spectra of
tissue and cells unless present at very high levels. Nevertheless, the
aconitase signal, with a maximum at around g = 2.02, has been suc-
cessfully used as a marker for oxidative stress in biological materials
[6,154,155,157].
14. Conclusions and future perspectives
In this review, we discussed the use of speciﬁc chemical probes and
analytical methods in the detection of ROS formed in tumor cells in vitro
and in vivo as well as the use of the low-temperature EPR technique to
monitor oxidants formed from the endogenous redox-sensing protein,
aconitase, in tumor cells. This technique can be translated to the clinic
in that the surgically removed tumor tissues from patients can be
monitored by EPR at low temperatures. This may be the only technique
that will enable detection of the endomarkers of mitochondrial oxidants
in isolated human tumors. Monitoring changes in ROS formation in an
in vivo setting following drug resistance and metabolic reprogramming
in tumors can aid in the development of a precise and eﬀective anti-
tumor drug regimen. The newly discovered in vivo mitochondrial O2•–
and H2O2 probes can be used in patient-derived mice xenograft models.
The metabolic reprogramming that occurs in hypoxia and drug re-
sistance likely favors mitochondrial OXPHOS and possibly ROS stimu-
lation. An increased understanding of ROS in cancer biology will help
us better interpret the redox signaling and therapeutics, and it will help
reveal the paradoxical role of ROS and autophagy in tumor growth and
antitumor treatments.
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